Equillium Inc (EQ)
1.49
+0.02
(+1.36%)
USD |
NASDAQ |
May 31, 16:00
1.50
+0.01
(+0.67%)
After-Hours: 20:00
Equillium Research and Development Expense (Annual): 37.04M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 37.04M |
| December 31, 2022 | 37.55M |
| December 31, 2021 | 26.38M |
| Date | Value |
|---|---|
| December 31, 2020 | 19.38M |
| December 31, 2019 | 17.64M |
| December 31, 2018 | 4.943M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.64M
Minimum
2019
37.55M
Maximum
2022
27.60M
Average
26.38M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Janux Therapeutics Inc | 54.92M |
| Mersana Therapeutics Inc | 148.27M |
| Vera Therapeutics Inc | 78.22M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |